Definition
A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.
Interaction | References |
---|---|
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein] | R |
Interaction | References |
---|---|
AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein] | R |
Interaction | References |
---|---|
Bortezomib results in decreased expression of BRCA1 mRNA | R |
Interaction | References |
---|---|
AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein] | R |
Interaction | References |
---|---|
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein] | R |
Interaction | References |
---|---|
AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein] | R |
Interaction | References |
---|---|
Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein] | R |
Interaction | References |
---|---|
AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein] | R |
Interaction | References |
---|---|
[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein | R |
Interaction | References |
---|---|
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of PMAIP1 mRNA | R |